Electrode Density Requires OR Benefits

Precision’s near term challenge is not proving that it can pack more electrodes onto cortex, it is proving that more electrodes change what a neurosurgeon can get done in the room. Layer 7-T is a 1,024 electrode, single use cortical array cleared by the FDA in March 2025, but incumbent strips and grids already fit existing epilepsy and mapping workflows and often support smaller openings or simpler setups. A premium consumable only wins if hospitals can point to fewer passes, faster decisions, or better preservation of speech and motor function.

• Layer 7-T is built as a thin film array with 1,024 electrodes, 16 ribbon cables, and a yoke that connects into standard EEG gear. That means the product advantage is signal density at the brain surface, not a wholly new hospital stack. Hospitals will compare it against cheaper arrays that already plug into familiar recording systems.
  1 sacra 2 fda 3 fda 4 adtechmedical
• The real operating room benchmark is not raw channel count, it is whether denser coverage lets surgeons map eloquent cortex through less exposure. Precision positions Layer 7 around micro slit insertion and no open surgery in later BCI work, while incumbent vendors already market narrow body strips, perpendicular tail exits, and pre cut grids to fit burr holes, smaller craniotomies, and standard mapping cases.
  3 fda 4 adtechmedical 5 adtechmedical 6 diximedical
• This is also a contrast with other BCI companies. Synchron wins by avoiding open brain surgery and using catheter labs, while Neuralink pursues bandwidth through implanted threads and custom robotics. Precision sits between them, so its best case is to show much richer cortical maps than low density grids, without the procedural burden of penetrating implants.
  7 sacra 8 sacra 9 precisionneuro

If Precision can turn density into a repeatable clinical workflow advantage, temporary mapping becomes the beachhead for broader therapeutic and permanent BCI use. The product path is straightforward, first win surgeons with better intraoperative decisions, then use that installed clinical trust to expand into higher value implants where mapping quality matters even more.